ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)

Volume 17, 9 Issues, 2017

Download PDF Flyer

Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.992
5 - Year: 3.412

Upcoming Articles (E-Pub Abstracts ahead of Print)

Regulation of microRNAs by phytochemicals: a promising strategy for cancer chemoprevention

Sadegh Babashah, Babak Bakhshinejad, Maryam Tahmasebi Birgani , Katayoon Pakravan and William C Cho.

View Abstract

Therapeutic approaches for the treatment of epidermal growth factor receptor mutated lung cancer

Dhaval Sanchala, Lokesh K Bhatt and Kedar S Prabhavalkar.

View Abstract

Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer

Heena Singla, Anjana Munshi, Raja Paramjit Singh Banipal and Vinod Kumar.

View Abstract

The Structural Bioinformatics analysis of Biophenolic Lignan-Estrogen Receptor interaction

Farzaneh Mohamadyar-Toupkanlou, Mina Esfandiari, Mahshid Sadat Kashef-Saberi, Mahboubeh Kabiri Renani and Masoud Soleimani.

View Abstract

Evaluation of anti-cancer activity of stilbene and methoxydibenzo[b,f]oxepin derivatives

Damian Garbicz , Damian Mielecki , Michał Wrzesiński , Tomasz Pilżys, Michał Marcinkowski , Jan Piwowarski , Janusz Dębski, Ewelina Palak, Przemysław Szczeciński, Hanna Krawczyk and Elżbieta Grzesiuk.

View Abstract

Crizotinib versus chemotherapy on ALK-positive NSCLC :a systematic review of efficacy and safety

Mingxia Wang, Guanqi Wang, Haiyan Ma and Baoen Shan.

View Abstract

An update on circumventing multidrug resistance in cancer by targeting P-glycoprotein

Xiaoqian Yang, Xiaoduan Li, Zhenfeng Duan and Xipeng Wang.

View Abstract

Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents

Leila Farahmand, Parnaz Merikhian, Neda Jalili, Behrad Darvishi and Keivan Majidza.

View Abstract

p53-Mdm2 interaction inhibitors as novel nongenotoxic anticancer agents

Surendra Kumar Nayak, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra.

View Abstract

Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer

Noreen Akhtar and Ishrat Jabeen.

View Abstract

Chemosensitizing activity of histone deacetylases inhibitory cyclic hydroxamic acids for combination chemotherapy of lymphatic leukemia

Denis V. Mishchenko, Margarita E. Neganova, Elena N. Klimanova, Tatyana E. Sashenkova, Elena F. Shevtsova, Igor V. Vystorop, Vadim V. Tarasov, Ghulam Md Ashraf , Nagendra Sastry Yarla and Gjumrakch Aliev.

View Abstract

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Ilaria Zanellato, Donato Colangelo and Domenico Osella.

View Abstract

Fertility drugs and ovarian cancer

Aus Tariq Ali.

View Abstract

The Complexity of DEK Signaling in Cancer Progression

Yong Teng, Liwei lang and Catherine E Jauregui.

View Abstract

Cancer-targeted oncolytic adenoviruses for modulation of the immune system

Vincenzo Cerullo, Cristian Capasso, Markus Vähä-Koskela, Otto Hemminki and Akseli Hemminki.

View Abstract

Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science